Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuroinflammation in Alzheimer disease

  • Heneka, Michael T.
  • Flier, Wiesje M. van der
  • Jessen, Frank
  • Hoozemanns, Jeroen
  • Thal, Dietmar Rudolf
  • Boche, Delphine
  • Brosseron, Frederic
  • Teunissen, Charlotte E.
  • Zetterberg, Henrik
  • Jacobs, Andreas H.
  • Edison, Paul
  • RamÍrez, Alfredo
  • Cruchaga, Carlos
  • Lambert, Jean-Charles
  • Ruíz Laza, Agustín
  • Sánchez-Mut, José Vicente
  • Fischer, Andre
  • Castro, Sergio
  • Stein, Thor D.
  • Kleineidam, Luca
  • Wagner, Michael
  • Neher, Jonas J.
  • Cunningham, Colm
  • Singhrao, Sim K.
  • Prinz, Marco
  • Glass, Christopher K.
  • Schlachetzki, Johannes C. M.
  • Butovsky, Oleg
  • Kleemann, Kilian
  • De Jaeger, Philip L.
  • Scheiblich, Hannah
  • Brown, Guy C.
  • Landreth, Gary
  • Moutinho, Miguel
  • Grutzendler, Jaime
  • Gomez-Nicola, Diego
  • McManus, Róisín M.
  • Andreasson, Katrin
  • Ising, Christina
  • Karabag, Deniz
  • Baker, Darren J.
  • Liddelow, Shane A.
  • Verkhratsky, Alexei
  • Tansey, Malu
  • Monsonego, Alon
  • Aigner, Ludwig
  • Dorothée, Guillaume
  • Nave, Klaus-Armin
  • Simons, Mikael
  • Constantin, Gabriela
  • Rosenzweig, Neta
  • Pascual Bravo, Alberto
  • Petzold, Gabor C.
  • Kipnis, Jonathan
  • Venegas, Carmen
  • Colonna, Marco
  • Walter, Jochen
  • Tenner, Andrea J.
  • O'Banion, M. Kerry
  • Steinert, Joern R.
  • Feinstein, Douglas L.
  • Sastre, Magdalena
  • Bhaskar, Kiran
  • Hong, Soyon
  • Schafer, Dorothy P.
  • Golde, Todd
  • Ransohoff, Richard M.
  • Morgan, David
  • Breitner, John
  • Mancuso, Renzo
  • Riechers, Sean-Patrick
Increasing evidence points to a pivotal role of immune processes in the pathogenesis of Alzheimer disease, which is the most prevalent neurodegenerative and dementia-causing disease of our time. Multiple lines of information provided by experimental, epidemiological, neuropathological and genetic studies suggest a pathological role for innate and adaptive immune activation in this disease. Here, we review the cell types and pathological mechanisms involved in disease development as well as the influence of genetics and lifestyle factors. Given the decade-long preclinical stage of Alzheimer disease, these mechanisms and their interactions are driving forces behind the spread and progression of the disease. The identification of treatment opportunities will require a precise understanding of the cells and mechanisms involved as well as a clear definition of their temporal and topographical nature. We will also discuss new therapeutic strategies for targeting neuroinflammation, which are now entering the clinic and showing promise for patients., A.F. received funds from Germany’s Excellence Strategy (EXC 2067/1 390729940). A.J.T. is supported by the National Institutes of Health (NIH) grant (U54 AG054349). D.L.F. is supported by grant IK6BX004852-01 from the Department of Veterans Affairs. D.B. acknowledges support from the Medical Research Council UK, Alzheimer’s Research UK and the European Union. She thanks the UK Brain Banks and BRAIN UK for providing tissue for her studies. D.J.B. is supported by the NIH (R01AG053229, R01AG068076, U54AG079779), the Minnesota Partnership for Biotechnology and Medical Genomics (MNP #18.04), and the Glenn Foundation for Medical Research. C.Cunningham is funded by the Irish Research Council, National Institutes of Health, the Dutch Research Council (ZonMW) and Alzheimer’s Research UK. D.G.-N. was supported by grants from the Medical Research Council (MR/P024572/1, MR/Y004116/1). C.V. was supported by the RYC2022-036191-I, funded by MCIN/AEI/10.13039/501100011033 and European Social Fund Plus. C.T. is supported by the European Commission Marie Curie International Training Network, grant agreement No. 860197 (MIRIADE) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant No. 831434), EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, ZonMW, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, and Alzheimer Netherlands. C.T. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is a recipient of TAP-dementia, a ZonMw-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. D.M. is supported by ZEN24-1070221 from the Alzheimer’s Association and R01 AG055072, R01 AG077651, and P30 AG072931 from NIH. D.R.T. received support from Research Foundation – Flanders (FWO; G065721N), Stichting Alzheimer Onderzoek (SAO/FRA 2023/0009) and Alzheimer’s Association (22-AAIIA-963171). D.S. was supported by NINDS-R01NS117533, NIA-RF1AG068281 and NIH-R24OD036199. G.C. is supported by the NextGenerationEU and National Recovery and Resilience Plan, National Biodiversity Future Center and PE grant MNESYS (PE0000006). G.C.P. received funding from the German Science Foundation (PE1193/6-2), ERA-NET (MICRO-BLEEDs and TACKLE-CSVD), and the Fondation Leducq (Transatlantic Network of Excellence 23CVD03); he is a member of the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) excellence cluster ImmunoSensation2. G.D. thanks the Agence Nationale de la Recherche (grants #ANR-21-CE17-0054-01; #ANR-24-CE18-2770-02), Fondation Alzheimer, Fondation pour la Recherche Médicale, Fondation Pierre Deniker, Association France Alzheimer and Fondation Vaincre Alzheimer for funding his research. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe Research and Innovation Programme under grant agreement No. 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320). J.B. was supported by a research grant from the Canada Institute for Health Research. J.G. was funded by the JPB Foundation, the Cure Alzheimers Fund and The Alzheimer’s Association. J.C.M.S. is supported by a clinical fellowship from the Alzheimer’s Association (AACSF). J.V.S.-M. is supported by grants from the Pasqual Maragall Foundation (PMRP/2022/1184) and Spanish (PID2022-143263OB-I00) and Valencian (PROMETEO/2021/045) governments. K.-A.N. has been supported by grants from the DFG (TRR274), European Research Council (ERC; AdG MyeliNANO) and the Adelson Medical Research Foundation (AMRF). K.B. was funded by the NIH grant RF1NS083704. L.A. is supppoted by the Austrian Science Fund FWF Project #P35417-B. K.A. is the Edward F. and Irene Thiele Pimley Professor of Neurology and Neurological Sciences and is supported by NIH grants RF1 AG070839, RF1 AG079131, and RF1 AG080742, the Wu Tsai Neurosciences Institute Knight Initiative for Brain Resilience at Stanford University, and she is a Chan Zuckerberg Biohub-San Francisco Investigator. M.K.O. is supported by grant 80NSSC21K0542 from NASA. O.B. is funded by grants from NIH-STTR (R41AG073059), Cure Alzheimer Fund, BrightFocus Foundation (2020A016806), NIH/NIA (R01 AG051812), NIH (R01 AG054672), NIH (R01 AG075509), NIH (R01 NS088137-10), NIH (R21AG076982), and NIH/NINDS (R01 NS088137). R.Mancuso has funding from the ERC under the European Union’s Horizon 2020 Research and Innovation Programme (project no. 101041867 - XenoMicrogliaAD), Fonds voor Wetenschappelijk Onderzoek (grants No. G0C9219N, G056022N and G0K9422N), the Alzheimer’s Association USA (2018-AARF-591110, 2018-AARF-591110-RAPID, E2A-23-1148152, ABA-22-968700). He also receives funding from BrightFocus Foundation (A2021034S), SAO-FRA (grants No. 2021/0021 and SAO-FRA 20230019) and the University of Antwerp (BOF-TOP 2022-2025). R.McManus is supported by grants from the European Union Joint Programme Neurodegenerative Disease (JPND) (01ED2409B), the Alzheimer’s Association (24AARF-1243474) and from the DFG, under Germany’s Excellence Strategy – EXC2151 – 390873048, along with Project-ID 432325352 – SFB 1454. S.C.G. is supported by the Alzheimer Forschung Initiative e.V (Grant 21060), the Hertie Network of Excellence in Clinical Neuroscience (Grant 2021-1A-12), the Bonn Neuroscience Clinician Scientist Program (Neuro-aCSis), and the DFG (EXC2151–390873048). S.H. is supported by the UK Dementia Research Institute (UKDRI-1011) and the Chan Zuckerberg Initiative Neurodegeneration Network. J.J.N. is currently supported through Germany’s Excellence Strategy (EXC 2145 SyNergy– ID 390857198), the Else Kröner-Fresenius Stiftung (2018-A158), the Charitable Hertie Foundation (P1200024), the BrightFocus Foundation (A2021035S) and Alzheimer’s Association (ADSF-24-1345513-C). W.M.vdF. performs research at the Alzheimer Center Amsterdam as part of the neurodegeneration research programme of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The chair held by W.M.vdF. is supported by the Pasman Stichting. W.M.vdF. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.M.vdF. is a recipient of TAP-dementia (www.tap-dementia.nl), receiving funding from ZonMw (#10510032120003)., Peer reviewed